Objective-von Willebrand factor (VWF) is crucial to hemostasis, but also plays a role in inflammatory processes.
V on Willebrand factor (VWF) is a plasma glycoprotein (GP) that plays a crucial role in the hemostatic process by mediating platelet adhesion to the subendothelium after vascular injury. 1 Furthermore, VWF participates in processes beyond hemostasis, such as angiogenesis and inflammation. 2 Monoclonal antibodies directed against VWF have been instrumental in deciphering VWF structure-function relationships in vitro. However, being raised in rodents, these monoclonal antibodies are usually unsuitable for in vivo use in mice.
See accompanying editorial on page 1590
Recently, single-domain antibodies (sdAbs; also referred to as Variable Domain of Heavy Chain antibodies or nanobodies) 3 have become an elegant alternative to conventional antibodies. sdAbs are the recombinant derivatives of variable fragments of heavy chain-only antibodies that naturally occur in camelids. 3 With a molecular weight of ≈12 to 15 kDa, sdAbs are currently the smallest naturally derived antigenbinding fragments. Because of their small size, sdAbs display unique characteristics, such as ease of engineering, expression in microorganisms, such as Escherichia coli, folding capacity, and stability. 4 The single-chain nature of sdAbs allows them to be selected via phage display approaches, with the benefit to make monoclonal entities. One such sdAb targeting VWF is currently under clinical development by Ablynx (Alx-0081/Caplacizumab), but it recognizes only human and not murine VWF, limiting its use for research purposes. 5 Here, we describe a new sdAb that cross-reacts with both human and murine VWF. This sdAb, designated KB-VWF-006, has been obtained after immunization of a llama with both human and murine VWF. KB-VWF-006 recognizes an epitope located within the A1 domain of VWF. We have used this unique research tool to demonstrate that the A1 domain is crucial to VWF-mediated inflammation in vivo.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Selection of VWF-Specific sdAb
sdAb libraries were constructed from lymphocytes isolated at 4 and 6 weeks after the first immunization. VWF-specific sdAb was selected via phage display screening using purified recombinant human VWF. After 2 rounds of panning, 137 of 192 analyzed clones specifically recognized VWF. DNA sequencing of the clones identified 17 unique sequences, and 13 were expressed in E coli Shuffle cells. We first searched for sdAbs blocking the interaction between the VWF A1 domain and its platelet receptor GP Ibα in both human and murine systems. Binding of sdAbs to the VWF A1 domain was therefore tested and one displayed selective binding to this domain, whereas no binding was observed to other domains tested, that is, the D'D3, A2, A3, and D4 domains ( Figure IA in the online-only Data Supplement). This sdAb, designated KB-VWF-006, also showed strong cross-reaction to murine, rat, and monkey VWF, but not to VWF from rabbit, dog, pig, or cow ( Figure IB in the online-only Data Supplement).
Kinetic analysis of the interaction between human and murine VWF with KB-VWF-006 was analyzed via Biolayer interferometry ( Figure II in the online-only Data Supplement), revealing apparent affinity constants in the pmol/L and nmol/L range, respectively. It should be noted that it is difficult, if not impossible to obtain true affinity constants given that VWF is a heterogeneous protein consisting of multiple covalently coupled subunits. To further enhance the avidity of the sdAb for VWF, a bivalent variant was constructed, designated KB-VWF-006bi, in which 2 copies of sdAb were separated by a linker consisting of 3 Ala residues. KB-VWF-006bi kept its specificity for the VWF A1 domain, as well as its capacity to interact with murine VWF. However, the bivalent variant was at least 20-fold more efficient in binding to either human or murine VWF ( Figure IIC through IIE in the online-only Data Supplement). The effect of valency at the level of VWF and sdAb was further illustrated in solid-phase inhibition experiments using monomeric and dimeric A1 domain fragments, showing the interaction between dimeric A1 domain/bivalent sdAb being 4-to 5-fold more efficient than monomeric A1 domain/monovalent sdAb interactions ( Figure IIF and IIG in the online-only Data Supplement).
KB-VWF-006bi Blocks VWF-GP Ib Interaction In Vitro and In Vivo
KB-VWF-006bi interfered dose dependently (IC 50 =0.8±0.1 μg/mL) with ristocetin-induced platelet aggregation in a system using purified human VWF and washed platelets ( Figure 1A) . A similar inhibition was observed when using platelet-rich plasma (not shown). KB-VWF-006bi blocked ristocetin-induced platelet aggregation dose dependently when using murine VWF and washed murine platelets ( Figure 1B) . KB-VWF-006bi did not affect ADP-, collagen-, or PAR1-activating peptide-induced human platelet aggregation (not shown). Furthermore, KB-VWF-006bi partially interfered with VWF binding to collagen VI ( Figure III in the onlineonly Data Supplement), but not with binding to collagens I, III, or IV (not shown).
In a whole blood perfusion assay, KB-VWF-006bi dose dependently reduced adhesion of human platelets when whole blood was perfused over a collagen matrix at a shear rate of 1200 s −1 (IC 50 =1.2±0.2 μg/mL; Figure 1C ). An example of reduced platelet adhesion at a concentration of 5 μg/mL KB-VWF-006bi is presented in Figure 1D . A similar concentration of KB-VWF-006bi (ie, 5 μg/mL) reduced platelet adhesion by 74±2% when murine whole blood was perfused over a collagen matrix under similar conditions ( Figure 1E ).
In vivo, using a tail clip bleeding model, KB-VWF006bi prolonged bleeding time and increased blood loss in a dose-dependent manner, in wild-type mice ( Figure IVA and IVB in the online-only Data Supplement). At a dose of 3.3 mg/kg and higher, the majority of mice displayed a clear bleeding tendency. KB-VWF-006bi also reduced the formation of occlusive thrombi in both mesenteric venules (low shear conditions) and arterioles (high shear conditions) in a ferric chloride-induced thrombosis model ( Figure IVC in the online-only Data Supplement). Control experiments showed that infusion of KB-VWF-006bi did not significantly alter VWF levels nor did it induce VWF degradation (not shown).
KB-VWF-006bi Reduces Vascular Permeability and Leukocyte Recruitment Induced by Inflammation
Previously, it has been reported that VWF actively contributes to the inflammatory response by promoting leukocyte recruitment and increasing vascular permeability. [6] [7] [8] [9] We investigated the effect of KB-VWF-006bi in 2 distinct models for inflammation: immune complex-mediated vasculitis (ICV) and irritant contact dermatitis. KB-VWF-006bi reduced myeloperoxydase activity (a measure for leukocyte recruitment) by 43% in the ICV model (1.4±0.2 versus 0.8±0.2 U/biopsy for control sdAb-treated and KB-VWF-006bi-treated mice, respectively; P=0.0025; Figure 2A ) and by 75% in the irritant contact dermatitis model (0.8±0.1 versus 0.2±0.2 U/biopsy for control sdAb-treated and KB-VWF-006bi-treated mice, respectively; P=0.0002; Figure 2B ). The inhibitory effect of KB-VWF-006bi seems to be dependent on the presence of platelets, as after platelet depletion (>95%), no further inhibition of leukocyte recruitment was observed in the ICV model in the presence of KB-VWF-006bi (Figure 2A) .
Inflammation-induced vascular leakage was analyzed by assessing the influx of red blood cells into the extravascular space. This was significantly reduced by 50% by KB-VWF006bi in the ICV model (22±6 versus 11±2 μg hemoglobin/ biopsy for control sdAb-treated and KB-VWF-006bi-treated mice, respectively; P<0.0001; Figure 2C ) and to background levels in the irritant contact dermatitis model (16±3 versus 11±2 μg hemoglobin/biopsy for control sdAb-treated and KB-VWF-006bi-treated mice, respectively; P=0.039; Figure 2D ).
Discussion
In this study, we chose to search for llama-derived sdAb that would cross-react with human and murine VWF. The advantage of such sdAbs is that they can be used in parallel while studying human VWF in vitro and murine VWF in vivo. The sdAb that was isolated for this study, that is, KB-VWF-006, bound efficiently to human VWF. Although the apparent affinity of KB-VWF-006 for murine VWF was 4 orders of magnitude less efficient, this sdAb was still able to bind murine VWF with low nanomolar affinity, which was further enhanced to subnanomolar affinity after dimerization. This high-affinity binding allowed us to select this sdAb for further functional studies in vitro and in vivo. We first demonstrated that KB-VWF-006bi strongly inhibited VWF-platelet interactions, and as a consequence, it efficiently inhibited VWF-dependent hemostasis in vivo.
Nonstandard Abbreviations and Acronyms
We and others have previously shown that VWF plays a role in the development of the inflammatory response. [6] [7] [8] [9] The contribution of VWF may involve direct interactions of the A1 and D'D3 domains with β2-integrins and PSGL-1 on leukocytes, 6 and in a platelet-dependent manner via interactions with GP Ibα. [7] [8] [9] In this study, we used KB-VWF006bi to investigate further the role of the VWF A1 domain in the inflammatory process by using 2 distinct models. Surprisingly, KB-VWF-006bi fully inhibited the vascular permeability in both models, as leakage of hemoglobin was reduced to background levels. Also leukocyte recruitment was reduced to background levels in the irritant contact dermatitis model and to near background levels in the ICV model. As KB-VWF-006bi binds to the VWF A1 domain, this suggests that the A1 domain is relevant to the proinflammatory activity of VWF. At this point, however, we cannot exclude that other domains contribute to this activity as well, either separately or cooperatively with the A1 domain. Importantly, the role of the A1 domain is at least partially dependent on the presence of platelets because no further reduction in leukocyte recruitment by KB-VWF-006bi was observed on platelet depletion (Figure 2A) . A conceivable scenario is that platelet binding to the A1 domain provides as condition that favors leukocyte recruitment. This would lead to the apparent paradoxical situation that blocking VWF-GP Ibα interactions may induce bleeding risks, although simultaneously it would reduce vascular leakage and leukocyte exfiltration under inflammatory conditions. Our results suggest that designing an anti-A1 antibody that would block VWF-dependent inflammation, while preserving its hemostatic activity, would be very challenging. Interestingly, sdAb ALX-0081/Caplacizumab (which blocks VWF-GP Ibα interactions similar to KB-VWF-006bi) is currently under clinical evaluation for its use in the management of thrombotic thrombocytopenic purpura, a disorder caused by the functional absence of ADAMTS13.
10 By using mouse models, it was observed that ADAMTS13 deficiency resulted in an exacerbated recruitment of leukocytes to inflamed vessels, and that this effect was dependent on the presence of VWF. 11 On the basis of our findings, it seems possible that ALX-0081/Caplacizumab may reduce the inflammatory side effects that occur in thrombotic thrombocytopenic purpura and other conditions characterized by ADAMTS13 deficiency.
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